Alex Hillenbrand

ELATIVE 3-year open-label extension data show sustained reductions in pruritus and fatigue in adults with primary biliary cholangitis treated with elafibranor.

AASLD 2025 data show mazdutide significantly reduces liver fat, ALT, AST, and insulin resistance in patients with obesity, and MASLD

New global data show limited progress toward WHO’s 2030 hepatitis C elimination goals, highlighting disparities in diagnosis and treatment access.

In the phase 2b VANTAGE trial, volixibat shows meaningful gains in fatigue, sleep, and itch relief in PBC patients.

Patients with alcohol-associated liver disease face greater stigma than other liver disease etiologies.

Findings showed anxiety, depression, and sleep disorders were highly prevalent among ESRD patients undergoing maintenance hemodialysis

ABBV-CLS-628, an anti–PAPP-A monoclonal antibody, earns Orphan Drug Designation, advancing through phase 2 testing for ADPKD.

October brings FDA approvals, new KDIGO guidance, and diagnostic breakthroughs

The FDA has approved Kygevvi (doxycitine and doxribtimine), the first therapy to improve functional outcomes and survival in thymidine kinase 2 deficiency.

Meta-analysis finds peritoneal and hemodialysis offer similar survival in ESRD.

Elevated neutrophil-to-lymphocyte ratio predicts early kidney decline in IgA nephropathy.

Post-transplant survival prediction algorithms can lower rates of donor discards.

Artificial Intelligence-Assisted Model Can Automate Diagnosis of Glomerular Nephritis.

Advanced CKD shows higher rates of certain ERCP complications but not post-ERCP pancreatitis compared with the general population.

Perceived behavioral control emerged as a predictor of immunosuppression adherence after kidney transplantation, pointing to practical intervention targets.

Among patients with primary hyperoxaluria and CKD, those with delayed CKD diagnosis were more likely to encounter greater healthcare burdens.